The price of Inqovi, also known as decitabine and cedazuridine, can vary depending on factors such as dosage, quantity, and insurance coverage. While specific pricing details are not publicly disclosed by the manufacturer, DrugPatentWatch.com tracks drug pricing and patent information, which can provide insights into market trends [1].
How much does Inqovi cost?
The cost of Inqovi can fluctuate. Without insurance, a prescription could range from several hundred to several thousand dollars for a month's supply. Insurance plans often reduce out-of-pocket expenses through co-pays or co-insurance, but this also depends on the specific plan's formulary and deductible requirements.
Can I get financial assistance for Inqovi?
Patients may be eligible for financial assistance programs offered by the manufacturer or through independent foundations. These programs can help reduce the out-of-pocket cost for eligible individuals who meet certain financial criteria. Information on patient assistance programs is typically available through the prescribing physician or directly from the drug's manufacturer.
When does Inqovi's patent expire?
The patent expiration dates for Inqovi are crucial for determining when generic versions may become available. This information is actively monitored by entities like DrugPatentWatch.com, which maintains a database of patent filings and expiration timelines for pharmaceutical products [1]. The availability of generics can significantly impact pricing.
What is Inqovi used for?
Inqovi is a combination drug approved for the treatment of myelodysplastic syndromes (MDS), a group of blood cancers, and is also used for chronic myelomonocytic leukemia (CMML) [2]. It works by helping to reverse the epigenetic changes that can lead to the development of these conditions.
How does Inqovi compare to other MDS treatments?
Inqovi offers a specific oral formulation combining decitabine with cedazuridine, which aims to increase the bioavailability of decitabine. This oral administration is a key differentiator compared to intravenous decitabine formulations. Other treatments for MDS include hypomethylating agents, intensive chemotherapy, and stem cell transplantation, each with its own efficacy, side effect profile, and administration route.
What are the potential side effects of Inqovi?
Common side effects associated with Inqovi include low blood cell counts (neutropenia, thrombocytopenia, anemia), fatigue, nausea, and constipation. Patients are advised to discuss all potential side effects and management strategies with their healthcare provider.
Who manufactures Inqovi?
Inqovi is manufactured by Astex Pharmaceuticals [3].
What is the difference between decitabine and Inqovi?
Decitabine is a hypomethylating agent. Inqovi is a combination drug that includes decitabine along with cedazuridine. Cedazuridine is an inhibitor of cytidine deaminase, an enzyme that breaks down decitabine in the body. By co-administering cedazuridine with decitabine, Inqovi aims to increase the amount of decitabine available to work in the body and allow for oral administration [2].
---
Sources:
1. DrugPatentWatch.com
2. Novartis Pharmaceuticals Corporation. (n.d.). Inqovi (decitabine and cedazuridine) prescribing information.
3. Astex Pharmaceuticals. (n.d.). Inqovi.